Savara, Inc. (SVRA)
5.21
+0.07
(+1.36%)
USD |
NASDAQ |
May 27, 14:57
Savara Cash from Investing (Quarterly) : 38.78M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Spyre Therapeutics, Inc. | 56.58M |
| ACADIA Pharmaceuticals, Inc. | 66.28M |
| Alnylam Pharmaceuticals, Inc. | -25.54M |
| Amgen, Inc. | -716.00M |
| Biogen, Inc. | -209.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -33.05M |
| Cash from Financing (Quarterly) | -0.195M |
| Free Cash Flow | -106.97M |
| Free Cash Flow Per Share (Quarterly) | -0.1307 |
| Free Cash Flow to Equity (Quarterly) | -33.30M |
| Free Cash Flow to Firm (Quarterly) | -33.10M |
| Free Cash Flow Yield | -8.86% |